We hosted a Research Update!

December 8, 2021; 3:30-4:30pm ET (US)

A conversation with Drs. Jean Bennett and Katherine Uyhazi

JeanBennett-300x248.jpg
katherine-uyhazi.1dada2ed.png
 

We were honored to have Drs. Jean Bennett and Katherine Uyhazi discuss their research on gyrate atrophy and the research trends they are seeing for inherited retinal diseases. Dr. Bennett was the lead researcher that led to the development of Luxturna, the first gene therapy for a retinal disease. Their research is funded in part by Conquering Gyrate Atrophy. The conversation was moderated by Dr. Karabi Acharya, Founder of Conquering Gyrate Atrophy and included opportunities for audience questions.

Dr. Bennett is a physician-scientist with expertise in molecular biology, vector development and gene therapy translational studies. She has established a true “from bench to bedside” program, and was the scientific leader of a team that translated reversal of blindness in animal models to demonstration of efficacy and safety in children and adults. This work led to the first and only approved gene therapy for inherited disease in USA and in Europe and the first approved gene therapy product targeting a retinal disease worldwide.

 

Dr. Uyhazi received her B.S. from The College of New Jersey, summa cum laude, and her MD/PhD from Yale School of Medicine with her PhD in Cell Biology. She completed her residency in ophthalmology and her fellowship in retinal degenerations at the Scheie Eye Institute at the University of Pennsylvania.   She is currently an Assistant Professor of Ophthalmology at Penn where she has a clinical practice for inherited retinal diseases and also runs a lab focused on developing new gene therapy and stem cell therapies for retinal diseases.